



Company Overview



 Manufacturer of consumables and equipment for mining and industry, for X-Ray Fluorescence (XRF) analysis – a powerful, long-established analytical technique, vital to the discovery, evaluation, qualification and production of most metals and control of material manufacturing processes

X-Ray Flux and chemicals

Platinum Labware and Precision Platinum Products Specialised furnaces and laboratory equipment

X-ray Flux Pre-fixed lithtum Bearter Blue Type: (6.8) ejectromote Accessed 8:44 (2014) Statute Statute Statute Statute Statute Statute Statute Statute Statute Net Statute Statute Statute Statute Statute Net Statute	Artisou Filux Pre facel Utilium Renze Fila Filosof (Service) Artisou Filosof 633 Utilium Focalement (Service 643) 633 Utilium Focalement (Service 643) 643 Utilium Focalement (Service 643) Artifisor	X-ray Flux Deficed Ethin Rotate Flux Vie 1050 Distantian Viet 1050 Distantian Viet Statistic Methoder II (1997 March 1997 2015 Ethin Methoder II (1997 March 1997 March 1997 2015 Ethin Methoder II (1997 March 1997 March 1997 2015 Ethin Methoder II (1997 March 1997 March
	Bendri & 198837A Densit of absentions (the final set of a	ent of device spectra entry







The XRF Analysis Process







The samples are then processed into a fine dust








The glass disk is presented into an x-ray spectrometer for analysis

The sample dust is then fused into a glass bead using **XRF Scientific's products**

Our Products





- Production
- Shipping
- Exploration

Materials:

- Cement
- Steel
- Glass
- Ceramics
- Research
- Education

Minerals:

- Iron ore
- Nickel
- Copper
- Aluminium
- Bauxite
- Manganese
- Uranium
- Lithium
- Mineral sands
- Commercial labs

Full Year Results – Overview



	Full Year Results			
(\$m)	2020	2019	2018	2017
Sales revenue	29.1	29.0	24.2	21.5
Profit before tax	4.5	3.2	1.5	1.0
Net profit after tax	3.1	2.1	1.0	0.8
Earnings per share (cents)	2.3	1.6	0.8	0.6
Weighted average no. of shares	133,825,803	133,825,803	133,825,803	133,825,803
Dividends (cents per share)	1.4	1.0	0.30	0.24
Dividend payout ratio	60%	63%	39%	40%

Adjusted Profit Before Tax (\$)	FY2020	FY2019
Profit before tax	4,454,254	3,151,229
COVID-19 wages subsidies	(212,729)	
COVID-19 other grants/subsidies	(74,776)	
COVID-19 payroll tax refunds	(82,837)	
Interest on early loan repayment	22,496	
Redundancy and other employee payments	97,328	
Adjusted profit	4,203,736	3,151,229

Adjusted Profit Before Tax (Quarterly) (\$)	FY2020
September 2019	913,028
December 2019	1,359,378
March 2020	986,378
June 2020	944,952
Total	4,203,736

Balance Sheet

(\$m)	2020	2019	Change
Cash and cash equivalents	3.6	3.2	12%
Trade and other receivables	3.8	4.1	(7%)
Inventories	11.2	8.7	30%
Other assets	0.4	0.4	(2%)
Property, plant and equipment	8.3	8.4	(1%)
PPE lease asset*	1.0	0.0	100%
Intangible assets	15.9	16.0	(1%)
Deferred tax asset	0.9	0.9	(4%)
Total assets	45.1	41.7	8%
Trade and payables			
- platinum loan provisions	4.2	2.0	115%
- other items	2.6	3.0	(14%)
Debt (short term)	0.1	0.7	(84%)
Debt (long-term)	0.8	1.6	(47%)
Current lease liabilities*	0.4	0.0	100%
Non-current lease liabilities*	0.6	0.0	100%
Income tax liability	0.5	0.4	9%
Deferred tax liability	0.3	0.2	28%
Total liabilities	9.5	7.9	21%
Total equity	35.6	33.8	5%



Net cash position of \$2.7m (2019: \$1m)

 *Arises from adoption of AASB 16 since 1 July 2019. See Note 18 of the Annual Report for further details

\$1.32m reduction of debt

 Additional on-balance sheet platinum loans of \$1.9m drawn in 2H, relating to refinancing of existing off-balance sheet platinum leases.
Platinum loans account for \$4.2m of total inventories



(\$m)	2020	2019
Net cash inflow from operating activities	4.2	3.8
Net cash (outflow) from investing activities	(0.8)	(0.6)
Net cash inflow/(outflow) from financing activities	(3.1)	(0.4)
Cash at start of period	3.2	0.4
Net increase/(decrease) in cash	0.4	2.8
Cash at end of period	3.6	3.2


Highlights:

- \$1.34m dividends paid (FY19: \$401k)
- \$1.32m debt reduction

Consumables



(\$m)	FY20	FY19
Sales revenue	8.9	8.0
Change in %	11%	6%
NPBT	2.5	2.2
Change in %	18%	35%
Margin %	29%	27%



• Overview of FY20:

- Revenue up 11% on FY19
- NPBT up 18% on FY19
- No notable impact from COVID-19
- Conditions buoyant in the mining sector across production and exploration
- New customers acquired during FY19 now delivering regular revenue


Outlook:

- Sales conditions from FY20 have so far continued into FY21
- New customer acquisitions expected
- COGS stable on FY20

Capital Equipment



FY20	FY19	
8.0	9.2	
(13%)	29%	
0.6	0.6	
(7%)	244%	
7%	7%	
	8.0 (13%) 0.6 (7%)	




• Overview of FY20:

- Revenue down 13% on FY19
- NPBT down 7% on FY19
- Positive conditions for first three quarters. Difficult Q4 as customers retracted CAPEX demand
- Margin improvement from increased proportion of end user sales / product mix sold and reduction in operating costs
- Outlook:
 - Large resurgence of CAPEX demand in July with order books now at above average levels.
 Customers proceeded with many projects that were temporarily halted in Q4
 - Progressing with R&D on two new machines, expecting launch this FY. One of which is into completely new adjacent market

Precious Metals



FY20	FY19	
13.2	13.1	
1%	19%	
1.4	0.9	
50%	1564%	
10%	7%	
	13.2 1% 1.4 50%	



• Overview of FY20:

- Revenue up 1% on FY19
- NPBT up 50% on FY19
- Revenue from Germany office \$3.04m vs \$2.82m in FY19. Growth was slower in 2H due to impact on Europe from COVID-19
- Domestic market remained strong through COVID-19 period, export market was affected by lockdowns
- Technical breakthroughs made at Melbourne factory, expanding industrial and semi-finished product lines – broadening the portfolio and bringing capability in-house
- Outlook:
 - Expecting continued growth from European operations
 - Overall market share continuing to grow globally
 - New platinum labware sales as a result of machines demand

Corporate Snapshot




Capital Structure

Shares on issue	133,825,803
Options on issue	Nil
Share price	29c
Market cap	\$38.8m
Cash (30/06/2020)	\$3.6m (2.7 cents per share)
Debt (30/06/2020)	\$0.9m (0.7 cents per share)
Enterprise Value	\$36.1m

Directors & Management

Fred Grimwade	Non Executive Chairman
Vance Stazzonelli	Chief Executive Officer
David Brown	Non Executive Director
David Kiggins	Non Executive Director

Share Price Performance – 1 Year



Shareholder Breakdown

Directors & Management	14%
Top 20 Shareholders	53%

Contact Information

Tel: (08) 9244 0600 86 Guthrie St. Osborne Park WA

Vance Stazzonelli – CEO vance@xrfscientific.com

Disclaimer



No responsibility for contents of Investor Presentation

•To the maximum extent permitted by law, XRF Scientific Limited and representatives:

•make no representation, warranty or undertaking, express or implied, as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient;

•accept no responsibility or liability as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient; and

•accept no responsibility for any errors or omissions from this Investor Presentation whether arising out of negligence or otherwise.

Accuracy of projections and forecasts

•This Investor Presentation includes certain statements, opinions, estimates, projections and forward-looking statements with respect to the expected future performance of XRF Scientific Limited. These statements are based on, and are made subject to, certain assumptions which may not prove to be correct or appropriate. Actual results may be materially affected by changes in economic and other circumstances which may be beyond the control of XRF Scientific Limited. Except to the extent implied by law, no representations or warranties are made by XRF Scientific Limited, its advisers or representatives as to the validity, certainty or completeness of any of the assumptions or the accuracy or completeness of the forward-looking statements should not be relied on as an indication of future value or for any other purpose.

No offer to sell or invitation to buy

•This Investor Presentation does not, and should not be considered to, constitute or form part of any offer to sell, or solicitation of an offer to buy, any shares in XRF Scientific Limited, and no part of this Investor Presentation forms the basis of any contract or commitment whatsoever with any person.

This Investor Presentation does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not permitted under applicable law. Distribution of this Investor Presentation in or from certain jurisdictions may be restricted or prohibited by law. Recipients must inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. Neither XRF Scientific Limited, its advisers or representatives accept any liability to any person in relation to the distribution or possession of this Investor Presentation from or in any jurisdiction.